Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2022 | Pre-symptomatic diagnosis of AL amyloidosis with biomarker-based screening in patients with MGUS

Silvia Mangiacavalli • 7 Sep 2022
ISA 2022
Amyloidosis Rare Diseases

Silvia Mangiacavalli, MD, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy, shares the results of a study investigating the possibility of diagnosing pre-symptomatic AL amyloidosis in patients with monoclonal gammopathy of undetermined significance (MGUS) using a biomarker-based screening program. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals